Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

What's In Store For Fulgent Genetics (FLGT) Q4 Earnings?

By Zacks Investment ResearchStock MarketsFeb 23, 2020 08:28PM ET
www.investing.com/analysis/whats-in-store-for-fulgent-genetics-flgt-q4-earnings-200510027
What's In Store For Fulgent Genetics (FLGT) Q4 Earnings?
By Zacks Investment Research   |  Feb 23, 2020 08:28PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Fulgent Genetics, Inc. (NASDAQ:FLGT) is expected to release fourth-quarter 2019 results on Feb 27, after the closing bell. In the last reported quarter, the company delivered a positive earnings surprise of 250%. Further, it has a trailing four-quarter positive surprise of 75%, on average.

Q4 Estimates

Currently, the Zacks Consensus Estimate for fourth-quarter 2019 revenues is pegged at $9 million, suggesting growth of 58.8% from the year-ago reported figure. The consensus mark for earnings is pegged at 6 cents per share, indicating a whopping improvement of 700% from the year-ago reported figure.

Factors at Play

Strength across its business and elevated test volumes is likely to have driven Fulgent Genetics’ fourth-quarter performance.

With respect to critical core business, the company is likely to have experienced solid demand for both its oncology test and reproductive health business. When it comes to oncology, there has been a consistent rise in demand for hereditary cancer panels. Moreover, rapid turnaround time and competitive pricing have been fueling notable growth in volume, thereby positioning oncology to become growing part of the company’s revenue sector. Consequently, this trend is likely to get reflected in Fulgent Genetics’ fourth-quarter performance.

With regard to genetic testing offering and tests, the company introduced Picture Genetics – a new line of at-home genetic testing offerings for the everyday consumer during the third quarter of 2019. This will offer enhanced genetic testing results to consumers directly and help them to make an informed decision about their health.

In the third quarter, the company unveiled a new test for reproductive health, which is now available for consumers. The launch of PGT-A test enables a woman to do the IVF process and to have greater control over embryo selections and the transfer, thereby increasing the probability of a healthy pregnancy. Another test that deserves a mention is Fulgent Genetics’ Parenting and the Wellness tests that are currently available online.

These tests have been driving the company’s growth along with expanding test offerings. These, in turn, are likely to have significantly contributed to the fourth-quarter top-line. In fact, per management, fourth-quarter 2019 revenues are projected to be around $8 million, reflecting a year-over-year growth of about 50%.

The company has been witnessing ongoing improvements in cost per test that continues to gain from operational efficiencies, thereby improving gross margin.

However, the company might have experienced higher operating expenses that are likely to have weighed on the company’s overall fourth-quarter performance.

What Our Quantitative Model Suggests

Per our proven model, a combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here as you will see.

Earnings ESP: Fulgent Genetics has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.

Zacks Rank: Fulgent Genetics carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here.

Stocks Worth a Look

Here are a few medical stocks worth considering with the right combination of elements to beat on earnings this reporting cycle.

Baxter International Inc. (NYSE:BAX) has a Zacks Rank #3 and an Earnings ESP of +0.19%.

HealthEquity, Inc. (NASDAQ:HQY) has a Zacks Rank of #3 and an Earnings ESP of +27.27%.

Nevro Corp. (NYSE:NVRO) is Zacks #2 Ranked and has an Earnings ESP of +3.45%.

Just Released: Zacks’ 7 Best Stocks for Today

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.7% per year.

These 7 were selected because of their superior potential for immediate breakout.

See these time-sensitive tickers now >>



Baxter International Inc. (BAX): Free Stock Analysis Report

HealthEquity, Inc. (HQY): Free Stock Analysis Report

Nevro Corp. (NVRO): Free Stock Analysis Report

FULGENT GENETIC (FLGT): Free Stock Analysis Report

Original post

Zacks Investment Research
What's In Store For Fulgent Genetics (FLGT) Q4 Earnings?
 

Related Articles

Tim Knight
Holy Frijoles By Tim Knight - May 20, 2022 4

I’ve never liked Chipotle (NYSE:CMG) food, and it’s heartening to see that about $800 has already been blown off of its absurd (former) $2,000/share price. I’d say it has precious...

What's In Store For Fulgent Genetics (FLGT) Q4 Earnings?

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email